MiMedx Group develops and markets regenerative biologics derived from human placental tissue for advanced wound care and surgical applications. Flagship allograft products such as EpiFix and AmnioFix are used by clinicians to support healing in chronic wounds, soft-tissue repair, and related procedures. Hospitals, wound centers, and surgical practices are the primary customers for these tissue-based therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 98.6 | — | 9.6 | — |
| Q3 2025 | 113.7 | — | 16.8 | — |
| Q4 2025 | 118.1 | — | 15.2 | — |
| Q1 2026 | 59 | — | -10.9 | — |
| Q2 2026 | 64.4 | -34.7% | -14.8 | -254.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Annexon, Inc. (ANNX), Village Super Market, Inc. (VLGEA), Design Therapeutics, Inc. (DSGN), Capital Bancorp, Inc. (CBNK), Priority Technology Holdings, Inc. (PRTH), Hingham Institution for Savings (HIFS)